SCHEMBL7004955

SCHEMBL7004955

Cc1nc2[nH]c(=O)[nH]c(=O)c2n1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GDA Q9Y2T3 2/20 0.49
PDE3B Q13370 3/20 0.37
PDE3A Q14432 3/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 2/20 0.37
HSD17B10 Q99714 2/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NOD1 Q9Y239 1/20 0.35
RPS6KA3 P51812 1/20 0.34
PMP22 Q01453 2/20 0.33
DPP4 P27487 1/20 0.33
PABPC1 P11940 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
CYP2C19 P33261 1/20 0.33
RAB9A P51151 1/20 0.33
BLM P54132 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18989874 0.79 GDA (0.47) GDAKDM4EALDH1A1CYP1A2HSD17B10
SCHEMBL9387974 0.73 GDA (0.38) GDAPDE3BPDE3AKDM4EALDH1A1
SCHEMBL9386888 0.72 GDA (0.37) GDAPDE3BPDE3AKDM4EALDH1A1
SCHEMBL874548 0.72 ALDH1A1 (0.39) GDAALDH1A1NOD1DPP4ADORA2B
SCHEMBL7403405 0.71 GDA (0.40) GDAKDM4EALDH1A1MAPTNPSR1
SCHEMBL12323353 0.70 PDE2A (0.33) PDE3BPDE3AKDM4EALDH1A1MAPT
SCHEMBL6876786 0.69 GAA (0.58) KDM4EALDH1A1HSD17B10GAANPSR1
SCHEMBL789315 0.68 NPC1 (0.50) GDAKDM4EALDH1A1CYP1A2HSD17B10
SCHEMBL789316 0.68 NPC1 (0.50) GDAKDM4EALDH1A1CYP1A2HSD17B10
SCHEMBL12958953 0.67 PNP (0.46) KDM4EALDH1A1CYP1A2HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250381198-A1 MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT 2025-12-18 US disclosed
US-20240415848-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT 2024-12-19 US disclosed
US-12083126-B2 Pharmaceutical compositions and methods for anesthesiological applications MELT PHARMACEUTICALS, INC. (US) 2024-09-10 US disclosed
US-20240207285-A1 MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT 2024-06-27 US disclosed
CN-115023503-A Method for producing closed linear DNA 泰瑞斯疗法公司 2022-09-06 CN disclosed
US-20220249510-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT 2022-08-11 US disclosed
US-20210085691-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT 2021-03-25 US disclosed
US-20200297734-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT 2020-09-24 US disclosed
US-10391102-B2 Pharmaceutical compositions and methods for anesthesiological applications MELT PHARMACEUTICALS, INC. (US) 2019-08-27 US disclosed
US-20190142841-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS HARROW IP, LLC 2019-05-16 US disclosed
EP-3389664-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF Raze Therapeutics Inc. (US) 2018-10-24 EP disclosed
US-20180271877-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT 2018-09-27 US disclosed
US-20180177797-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT 2018-06-28 US disclosed
US-20180177796-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT 2018-06-28 US disclosed
US-9918993-B2 Pharmaceutical compositions for anesthesiological applications IMPRIMIS PHARMACEUTICALS, INC. (US) 2018-03-20 US disclosed
WO-2017106352-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-06-22 WO disclosed
US-20160367566-A1 PHARMACEUTICAL COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT 2016-12-22 US disclosed
US-8828990-B2 N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use GENENTECH, INC. (US) 2014-09-09 US disclosed
EP-1301187-A2 HETEROCYCLIC COMPOUNDS, WHICH ARE INHIBITORS OF THE ENZYME DPP-IV NOVO NORDISK A/S (DK) 2003-04-16 EP disclosed
WO-2002002560-A2 PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) NOVO NORDISK A/S (DK) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220249510-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS GRIN3A, OPRK1, GRIN2B GDA 2968/4885PDE3B 1025/4885PDE3A 870/4885
US-20180177797-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS GRIN2B, GRIN3A, GABRA5 GDA 2860/4885PDE3B 1416/4885PDE3A 1280/4885
US-10391102-B2 Pharmaceutical compositions and methods for anesthesiological applications GRIN2B, GRIN3A, GABRA5 GDA 2902/4885PDE3B 1419/4885PDE3A 1291/4885
US-20190142841-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS GRIN3A, OPRK1, GRIN2B GDA 2968/4885PDE3B 1025/4885PDE3A 870/4885
US-20240415848-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS GRIN3A, OPRK1, GRIN2B GDA 2968/4885PDE3B 1025/4885PDE3A 870/4885
US-20240207285-A1 MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION KCNA3, OPRK1, KCNA7 GDA 3613/4885PDE3B 1417/4885PDE3A 936/4885
US-20160367566-A1 PHARMACEUTICAL COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS GRIN2B, GRIN3A, GABRB1 GDA 2448/4885PDE3B 772/4885PDE3A 853/4885
US-20200297734-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS GRIN3A, OPRK1, GRIN2B GDA 2968/4885PDE3B 1025/4885PDE3A 870/4885
US-20210085691-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS GRIN2B, GRIN3A, GRIN1 GDA 3080/4885PDE3B 1552/4885PDE3A 1398/4885
US-20250381198-A1 MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION KCNA3, OPRK1, KCNA7 GDA 3613/4885PDE3B 1417/4885PDE3A 936/4885
US-20180177796-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS GRIN2B, GRIN3A, GABRA5 GDA 2860/4885PDE3B 1416/4885PDE3A 1280/4885
US-20180271877-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS GRIN2B, GRIN3A, GABRA5 GDA 2902/4885PDE3B 1419/4885PDE3A 1291/4885
US-12083126-B2 Pharmaceutical compositions and methods for anesthesiological applications GRIN3A, OPRK1, GRIN2B GDA 2968/4885PDE3B 1025/4885PDE3A 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.